Scholarlink

Background/objectives <p>To investigate if early detection of neovascular age-related macular degeneration (nAMD) in the second eye is associated with a reduced number of intravitreal treatments compared with the first eye using data from the EDNA/FASBAT trial.</p> Subjects/methods <p>Post-hoc analysis of 117 participants receiving standard clinical care during the FASBAT study. Assessments were at enrolment and at an average of 18.9 (SD = 10.2) and 30.5 (SD = 9.7) months in the first eye. Assessment of the second eye was made at the onset of nAMD (as participants were monitored for conversion) and at 12- and 24-months. The annualised injection rate for first eyes and the actual rate for second eyes are reported alongside visual acuity (VA) and optical coherence tomography (OCT) characteristics.</p> Results <p>In second eyes the annualised number of treatments was lower both in year 1 (second eyes mean = 6.4, SD = 3.4 vs mean = 7.2, SD = 1.9 in first eyes) and in year 2 (second eyes mean = 5.8, SD = 2.9; versus mean = 6.2, SD = 2.7 in first eyes). Second eyes had better VA at the point of conversion to nAMD (mean = 74.1, SD = 9.9) compared with the first eyes at baseline (mean = 55.6, SD = 15.3) which was maintained until 24 months (second eye: mean = 73.6, SD = 9.9; first eye: mean = 53.2, SD = 19.3). Highly reflective material was detected less frequently in second eyes compared to first eyes at clinical visits.</p> Conclusions <p>Compared to first eyes, early detection of nAMD in the second eye is beneficial in terms of better maintenance of visual acuity, reduced intravitreal treatment burden, and improved anatomical findings after 2 years of treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Early detection of neovascular age-related macular degeneration in the second eye reduces intravitreal treatment burden: FASBAT report 2

  • 期刊论文

  • 发表日期：

    2026年1月10日

查看全文
  • Rachel L. W. Hanson,
  • Archana Airody,
  • Sobha Sivaprasad,
  • Martin McKibbin,
  • Antony B. Morland,
  • Tunde Peto,
  • Usha Chakravarthy,
  • Richard P. Gale,
  • Richard P. Gale,
  • Sobha Sivaprasad,
  • Martin McKibbin,
  • Nicola Hopkins,
  • Louise Downey,
  • Geeta Menon,
  • Emily Fletcher,
  • Tunde Peto,
  • Ben Burton,
  • Mandeep Bindra,
  • Sergio Pagliarini,
  • Faruque Ghanchi,
  • Sarah MacKenzie,
  • Amy Stone,
  • Sheena George,
  • Sanjiv Banerjee,
  • Konidaris Vasileios,
  • Steven Dodds,
  • Savita Madhusudhan,
  • Chris Brand,
  • Andrew Lotery,
  • Diane Whistance-Smith,
  • Theo Empeslidis

摘要

Background/objectives

To investigate if early detection of neovascular age-related macular degeneration (nAMD) in the second eye is associated with a reduced number of intravitreal treatments compared with the first eye using data from the EDNA/FASBAT trial.

Subjects/methods

Post-hoc analysis of 117 participants receiving standard clinical care during the FASBAT study. Assessments were at enrolment and at an average of 18.9 (SD = 10.2) and 30.5 (SD = 9.7) months in the first eye. Assessment of the second eye was made at the onset of nAMD (as participants were monitored for conversion) and at 12- and 24-months. The annualised injection rate for first eyes and the actual rate for second eyes are reported alongside visual acuity (VA) and optical coherence tomography (OCT) characteristics.

Results

In second eyes the annualised number of treatments was lower both in year 1 (second eyes mean = 6.4, SD = 3.4 vs mean = 7.2, SD = 1.9 in first eyes) and in year 2 (second eyes mean = 5.8, SD = 2.9; versus mean = 6.2, SD = 2.7 in first eyes). Second eyes had better VA at the point of conversion to nAMD (mean = 74.1, SD = 9.9) compared with the first eyes at baseline (mean = 55.6, SD = 15.3) which was maintained until 24 months (second eye: mean = 73.6, SD = 9.9; first eye: mean = 53.2, SD = 19.3). Highly reflective material was detected less frequently in second eyes compared to first eyes at clinical visits.

Conclusions

Compared to first eyes, early detection of nAMD in the second eye is beneficial in terms of better maintenance of visual acuity, reduced intravitreal treatment burden, and improved anatomical findings after 2 years of treatment.